tetano
Editor, Senior Moderator
Br J Haematol
. 2020 Jun 25.
doi: 10.1111/bjh.16961. Online ahead of print.
Amelioration of COVID-19 Related Cytokine Storm Syndrome: Parallels to Chimeric Antigen receptor-T Cell Cytokine Release Syndrome
Ryan L Hoiland[SUP] 1 2 [/SUP], Sophie Stukas[SUP] 3 [/SUP], Jennifer Cooper[SUP] 3 [/SUP], Sonny Thiara[SUP] 4 [/SUP], Luke Y C Chen[SUP] 5 [/SUP], Catherine M Biggs[SUP] 6 [/SUP], Kevin Hay[SUP] 5 [/SUP], Agnes Y Y Lee[SUP] 5 [/SUP], Kamran Shojania[SUP] 7 [/SUP], Alym Abdulla[SUP] 5 [/SUP], Cheryl L Wellington[SUP] 3 [/SUP], Mypinder S Sekhon[SUP] 4 [/SUP]
Affiliations
Abstract
Coronavirus disease-2019 (COVID-19) severity appears to parallel the host immune response, with a subset of patients developing COVID-19 cytokine storm syndrome (CSS).(1) Serum inflammatory cytokines are elevated in COVID-19,(2-5) and interleukin (IL)-6 appears to play a central role in COVID-19 related CSS.(6-8) Based on the success of IL-6 receptor blockade for chimeric antigen receptor T-cell therapy associated cytokine release syndrome (CAR T-cell CRS), similar strategies using tocilizumab are being investigated in COVID-19.
. 2020 Jun 25.
doi: 10.1111/bjh.16961. Online ahead of print.
Amelioration of COVID-19 Related Cytokine Storm Syndrome: Parallels to Chimeric Antigen receptor-T Cell Cytokine Release Syndrome
Ryan L Hoiland[SUP] 1 2 [/SUP], Sophie Stukas[SUP] 3 [/SUP], Jennifer Cooper[SUP] 3 [/SUP], Sonny Thiara[SUP] 4 [/SUP], Luke Y C Chen[SUP] 5 [/SUP], Catherine M Biggs[SUP] 6 [/SUP], Kevin Hay[SUP] 5 [/SUP], Agnes Y Y Lee[SUP] 5 [/SUP], Kamran Shojania[SUP] 7 [/SUP], Alym Abdulla[SUP] 5 [/SUP], Cheryl L Wellington[SUP] 3 [/SUP], Mypinder S Sekhon[SUP] 4 [/SUP]
Affiliations
- PMID: 32584416
- DOI: 10.1111/bjh.16961
Abstract
Coronavirus disease-2019 (COVID-19) severity appears to parallel the host immune response, with a subset of patients developing COVID-19 cytokine storm syndrome (CSS).(1) Serum inflammatory cytokines are elevated in COVID-19,(2-5) and interleukin (IL)-6 appears to play a central role in COVID-19 related CSS.(6-8) Based on the success of IL-6 receptor blockade for chimeric antigen receptor T-cell therapy associated cytokine release syndrome (CAR T-cell CRS), similar strategies using tocilizumab are being investigated in COVID-19.